Products for Research Use Only
RegisterLogin

EGFR/CDK2-IN-2

CAT: 0804-HY-156114Size: 1 EachDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-156114Size:1 Each
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
EGFR/CDK2-IN-2 (compound 6a) is a dual inhibitor of EGFR and CDK-2 with IC50s of 19.6 and 87.9 nM, respectively. EGFR/CDK2-IN-2 induces apoptosis in MCF-7 cells and arrests the cell cycle in the S phase. EGFR/CDK2-IN-2 has significant anti-cancer cell toxicity and inhibits MCF-7 with an IC50 of 0.39 μM[1].
UNSPSC
12352005
Target
CDK; EGFR
Type
Reference compound
Related Pathways
Cell Cycle/DNA Damage; JAK/STAT Signaling; Protein Tyrosine Kinase/RTK
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/egfr-cdk2-in-2.html
Solubility
10 mM in DMSO
Smiles
O=C(C1=CN(C2=CC=CC=C2)N=C1C3=NN4C(SC3)=NN=C4CC5=NN=C6SCC(C7=NN(C8=CC=CC=C8)C=C7C(C9=CC=C%10C=CC=CC%10=C9)=O)=NN65)C%11=CC=C%12C=CC=CC%12=C%11
Molecular Formula
C49H32N12O2S2
Molecular Weight
884.99
References & Citations
[1]Salem M E, et al. Synthesis and Anti-Breast Cancer Potency of Mono-and Bis- (pyrazolyl [1, 2, 4] triazolo [3, 4-b][1, 3, 4] thiadiazine) Derivatives as EGFR/CDK-2 Target Inhibitors[J]. ACS Omega, 2023.. . .
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
No Development Reported

Related Products

CatalogName
HY-156116EGFR/CDK2-IN-4
HY-156115EGFR/CDK2-IN-3
HY-151573EGFR/CDK2-IN-1
HY-147797EGFR/HER2/CDK9-IN-2
HY-176124CDK2 ligand-2
HY-163815-01CDK2 degrader 2
HY-169048CDK2/4-IN-2
HY-100520-01EGFR-IN-2
HY-143497HDAC1/2 and CDK2-IN-1
HY-148214-01CDK2/4/6-IN-2

Alternative Products

CatalogName
T79727-01EGFR/CDK2-IN-2
T72844-01EGFR/CDK2-IN-1
MBS5821389EGFR/CDK2-IN-3
GTR19230314-01EGFR/CDK2-IN-4
GTR19274616-01EGFR/CDK2-IN-5
T200624-01CDK2/4-IN-2
T89344-01CDK2 degrader 2
T207428-01CDK2 ligand-2
244513CDK2 (Cyclin-Dependent Kinase 2, p33 (CDK2) )
MBS5766573EGFR-IN-2

Popular Products